BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37062213)

  • 1. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
    Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
    Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
    Perrone E; De Felice F; Capasso I; Distefano E; Lorusso D; Nero C; Arciuolo D; Zannoni GF; Scambia G; Fanfani F
    Gynecol Oncol; 2022 Jun; 165(3):585-593. PubMed ID: 35341588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
    Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
    Pasanen A; Loukovaara M; Bützow R
    Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
    de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
    Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
    Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
    J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
    Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
    Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
    Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
    Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
    Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
    Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
    J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
    Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
    Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.